GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lobe Sciences LOBE.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.04

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lobe Sciences

Its shares trade on Canadian Securities Exchange under the ticker LOBE.CN. It has been listed since 19 June 2012. In the fiscal year to 31 August 2024, it reported revenue of C$136,205 and a net loss of C$4.4m. At that date it held total assets of C$258,570 and shareholders' equity of −C$3.1m.

Lobe Sciences Ltd. is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to licensed cannabis businesses in the United States. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-06-19. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
19 Jun 2012

Leadership

Pay as last reported

  • Dr. Frederick SancilioExecutive Chairman of the Board, Chief Executive Officer, since 2024
  • Mr. Charles GoulburnPresident, Director, since 2024
  • Mr. Yong YaoChief Financial Officer, Executive Vice President
  • Dr. Harry JacobsonIndependent Director
  • Mr. Wesley RamjeetIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lobe Sciences Ltd. provides real estate and financial support to US cannabis businesses.
  • L-130 and L-131 are proprietary compounds for orphan disease treatment.
  • Altemia commercializes Sickle Cell Disease treatment in the US market.

Weaknesses

  • Lobe Sciences Australia Pty Ltd. operates in a different market segment.
  • Eleusian Biosciences Corp. focuses on drug research without commercialization.
  • Altemia & Company, LLC. is limited to Sickle Cell Disease treatment.

Opportunities

  • Collaborations with partners for drug R&D in orphan diseases.
  • Expansion of Altemia for additional rare disease treatments.
  • L-130 and L-131 address unmet medical needs in chronic cluster headaches.

Threats

  • Regulatory challenges in the US cannabis industry.
  • Competition in the orphan disease drug development sector.
  • Limited commercialization of Altemia beyond Sickle Cell Disease.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.